Treating Patients with Complex Metabolic Conditions

Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) is a late-stage clinical biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. Allena’s lead product candidate, ALLN-177, is a first-in-class, oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders.

Year Invested: 2011
Location: Newton, Mass.

Recent News

March 7, 2018
Allena Pharmaceuticals to Present at Cowen and Company 38th Annual Health Care Conference

March 6, 2018
Allena Pharmaceuticals Initiates First Phase 3 Trial for ALLN-177 in Patients with Enteric Hyperoxaluria

December 14, 2017
Allena Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update

Read More News

Associated Team Members

Robert Tepper, M.D.